Navidea Biopharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NAVB research report →
Companywww.navidea.com
Navidea Biopharmaceuticals, Inc. , a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs.
- CEO
- Craig A. Dais CPA
- IPO
- 1992
- Employees
- 11
- HQ
- Dublin, OH, US
Price Chart
Valuation
- Market Cap
- $10.01K
- P/E
- -0.00
- P/S
- 0.15
- P/B
- -0.00
- EV/EBITDA
- -0.03
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -259.40%
- Op Margin
- -21402.08%
- Net Margin
- -23117.58%
- ROE
- 355.34%
- ROIC
- 280.59%
Growth & Income
- Revenue
- $65.65K · -87.65%
- Net Income
- $-15,177,153 · -29.38%
- EPS
- $-0.59 · -47.50%
- Op Income
- $-14,050,895
- FCF YoY
- 11.10%
Performance & Tape
- 52W High
- $0.04
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 1.80
- Avg Volume
- 11.46K
Get TickerSpark's AI analysis on NAVB
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 27, 21 | Rosol Michael Stanley | other | 100,000 |
Our NAVB Coverage
We haven't published any research on NAVB yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NAVB Report →